Skip to content
★ Sign in to follow
Fuji Pharma Co.,Ltd. logo

Fuji Pharma Co.,Ltd. Stock: price and insider trades · Japan

富士製薬工業株式会社

JP·Mcap JP¥47.9BHealth Care

Fuji Pharma Co.,Ltd.: what insiders have been doing

Fuji Pharma Co.,Ltd., classified in the Health Care sector, is a listed company based in Tokyo, Japan, founded in 1965. Its insiders report their share dealings to EDINET (Japan FSA). Over the twelve months to 10 November 2026, 7 filings were filed, from 2 insiders.

The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

Over the last twelve months, not one insider purchase of Fuji Pharma Co.,Ltd. stock was filed. Between a trade and the moment it shows up on EDINET (Japan FSA), the median delay is 6 days. That lag is the time during which only the insider knows about the trade.

With 7 filings in twelve months, the company is more active than the median of 3 filings across the 3,419 companies we follow on the same exchange.

In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. This summary is built from EDINET (Japan FSA) disclosures alone and does not predict where the share price will go.

Key facts

Headquarters: Tokyo, Japan · Founded: 1965

Source: Wikidata (CC0).

Insider Decl.
11
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 10,973 of 26,911 companies
56.2
score / 100
Value
64
Quality
48
FCF yld4.2%
Earn yld6.5%
EV/EBITDA9.3x
ROE6.1%
Gross mgn40%
Net mgn5.8%
Debt/EBITDA3.7x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended September 2025 · cache

JP¥1,834
Analyst consensus
2 analysts
2.00/5
JP¥2,300Target JP¥2,950(+61%)JP¥3,600
Income statement
RevenueJP¥51.7B
Gross profitJP¥20.8B40% margin
EBITDAJP¥8.3B16% margin
Net incomeJP¥3B5.0% margin
Valuation
PER (trailing)15.3x
P/Book0.9x
Beta0.33
Balance sheet & cash
Market capJP¥47.9B
Total debtJP¥30.9B
Free Cash FlowJP¥1.9B
Debt / Equity56%
Profitability & ownership
ROE6.1%
ROA4.6%
% insiders41.1%
% institutions14.5%
Last declaration on 31 July 2026
Declarations11 total
  • ●
    Large shareholderExecutives
    8EDINET
    18.4% of flowShareXTKSEDINET:S100YOUW
  • ●
    Large shareholderExecutives
    7EDINET
    18.4% of flowShareXTKSEDINET:S100Y809
  • ●
    Large shareholderExecutives
    7EDINET
    18.3% of flowShareXTKSEDINET:S100Y1TH
  • ●
    Related company / holdingExecutives
    0EDINET
    ShareXTKSEDINET:S100XRM5
  • ●
    Related company / holdingExecutives
    0EDINET
    ShareXTKSEDINET:S100XOM2
  • ●
    Related company / holdingExecutives
    0EDINET
    ShareXTKSEDINET:S100XMJA
  • ●
    Related company / holdingExecutives
    7EDINET
    19.5% of flowShareXTKSEDINET:S100XKIN
  • ●
    Related company / holdingExecutives
    7EDINET
    16.4% of flowShareXTKSEDINET:S100WI4S
  • ●
    Related company / holdingExecutives
    11EDINET
    64.1% of flowShareXTKSEDINET:S100U7L5
  • ●
    Large shareholderExecutives
    7EDINET
    20.7% of flowShareXTKSEDINET:S100TBRL
  • ●
    Large shareholderExecutives
    7EDINET
    24.2% of flowShareXTKSEDINET:S100Q1CO

11 of 11 declarations

About Fuji Pharma Co.,Ltd.

Fuji Pharma Co., Ltd. is a Japanese company operating in the healthcare and pharmaceutical sector. It focuses on the research, development, and marketing of pharmaceutical products.